“Our focus for 2025 will be on advancing development of RPT904, a novel, potential best-in-class option to treat the large and underserved population of patients suffering from food allergy and chronic spontaneous urticaria,” said Brian Wong, President and CEO of RAPT. “We believe RPT904 can be a differentiated product to treat these diseases by targeting IgE, an approach validated by omalizumab. We expect to initiate a Phase 2b clinical trial for RPT904 in food allergy in the second half of 2025 and await clinical data later this year from our partner Jemincare to guide our development strategy in CSU.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPT:
- RAPT Earnings this Week: How Will it Perform?
- Rapt Therapeutics files to sell 176.45M shares of common stock for holders
- RAPT Therapeutics Plans Phase 2b Trials for RPT904
- RAPT Therapeutics Announces Leadership Changes and Realignment
- Rapt Therapeutics appoints Lyons-Williams as chair of board of directors
Questions or Comments about the article? Write to editor@tipranks.com